Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 225 of 227 entries
View as:

Humidified Forest Oils for Immune System Recovery in Stage I-III Breast or Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05012813 Org: User:
Start: 07/19/22 End: 12/31/25 Due: 12/31/26

Feasibility of OmnEcoil System for Integrated Endorectal MRI and Transrectal MRI-Targeted Biopsy of the Prostate

Phase: N/A Priority: Normal
NCT ID: NCT05362032 Org: User:
Start: 05/08/23 End: 07/30/27 Due: 07/30/28

MRI Assessment of Leukemia Response to Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01537159 Org: User:
Start: 05/31/12 End: 12/31/18 Due: 12/31/19

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05034627 Org: User:
Start: 08/09/22 End: 10/01/26 Due: 10/01/27

Pre-Prostatectomy Celecoxib or Placebo

Phase: N/A Priority: Normal
NCT ID: NCT02840162 Org: User:
Start: 05/31/01 End: 05/31/11 Due: 05/31/12

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04872790 Org: User:
Start: 09/02/22 End: 12/31/26 Due: 12/31/27

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04529044 Org: User:
Start: 01/01/25 End: 12/20/25 Due: 12/20/26

Fish Oil and Green Tea Extract in Preventing Prostate Cancer in Patients Who Are at Risk for Developing Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00253643 Org: User:
Start: 07/31/05 End: 12/31/13 Due: 12/31/14

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00238173 Org: User:
Start: 12/31/04 End: 02/17/06 Due: 02/17/07

Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML

Phase: N/A Priority: Normal
NCT ID: NCT00416884 Org: User:
Start: 05/31/03 End: 03/31/08 Due: 03/31/09

Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT06157099 Org: User:
Start: 09/01/24 End: 09/01/29 Due: 09/01/30

Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00243009 Org: User:
Start: 06/30/05 End: 04/30/06 Due: 04/30/07

Daptomycin in Treating Neutropenia and Fever in Patients With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00335478 Org: User:
Start: 12/31/06 End: 10/31/08 Due: 10/31/09

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06528210 Org: User:
Start: 04/16/25 End: 06/01/28 Due: 06/01/29

N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01138137 Org: User:
Start: 06/30/10 End: 12/31/14 Due: 12/31/15

Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00075387 Org: User:
Start: 03/07/03 End: 04/30/24 Due: 04/30/25

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

Phase: N/A Priority: Normal
NCT ID: NCT01253642 Org: User:
Start: 07/12/10 End: 09/15/17 Due: 09/15/18

Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00900055 Org: User:
Start: 06/30/75 End: 08/23/16 Due: 08/23/17

Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00822848 Org: User:
Start: 02/28/09 End: 04/30/13 Due: 04/30/14

Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02736617 Org: User:
Start: 07/05/16 End: 06/02/21 Due: 06/02/22

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04251715 Org: User:
Start: 04/28/21 End: 11/30/25 Due: 11/30/26

Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01748942 Org: User:
Start: 12/31/12 End: 03/29/17 Due: 03/29/18

Therapy to Prevent Sexual Pain in Breast Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT01539317 Org: User:
Start: 12/31/11 End: 11/30/13 Due: 11/30/14

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04539808 Org: User:
Start: 05/27/21 End: 10/05/25 Due: 10/05/26

Imatinib Mesylate in Treating Patients With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT00245128 Org: User:
Start: 08/31/05 End: 10/31/11 Due: 10/31/12